After my M Tech from BITS Pilani, i got placed with biotech pharma
R&D where in i was asked to choose my task from being a molecular biologist
to fermentation and further downstream processing. I chose to be a molecular
biologist, then went ahead for Pharma consulting and the journey
still continues. I have been working in the Biosimilar arena for around 8 years
with experience in working in R&D to CI in terms of PMR services
in terms of development of specific recombinant proteins and Mabs
In the late 2000's some big
pharma companies showed a big picture to the world related to their huge
investment in this arena and there were some who slowly started developing
their pipeline. With the block buster era loosing its glory...biosimilars will
mark the difference and emerging markets will be the bait for the big
pharma's....in present Europe has been the front runner for biosimilar
promotion but we can't negate the emerging markets (China, India and South
Korea).....they are the new junctures for growth and promotions of biosimilars
and will emerge as destination for biosimilar developments.......
